Melinda Yushak, MD, MPH | Authors

PHI - 2C

51 N 39TH ST


Advances in the Systemic Treatment of Metastatic Melanoma

May 15, 2013

Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.